Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Preventing Mood Disorders in High-risk Offspring: Protocol for the Randomized Controlled Trial of the MARIO Online Preventive Intervention Platform (MARIO)

9 november 2026 bijgewerkt door: Annabel Vreeker, Erasmus Medical Center

Children of parents with a mental illness (COPMI) have an increased likelihood of developing mood disorders such as major depressive disorder or bipolar disorder. Especially adolescence is a particularly vulnerable time for the development of mood disorders. It is therefore important to intervene early to prevent the development of mood disorder symptoms and fully established mood disorders. This proposed MARIO online preventive intervention trial aims to examine the potential effects of access to an online platform (the MARIO preventive intervention platform), that integrates three preventive online interventions, on the development of mood disorder symptoms in COPMI. With a target sample size of N = 154 offspring - aged between 10 to 25 years - of parents with a mental illness, the researchers will conduct one of the largest Randomized Controlled Trials (RCT) for online preventive interventions in a high-risk offspring population to date. Participants in the experimental condition will receive 3 months access to the MARIO online preventive intervention platform through which participants can take part in up to 3 online preventive interventions for mood disorders. These intervention components include content targeted at COPMI specifically, including psychoeducation, social support, the implementation of adaptive coping strategies, and improving affective awareness. The preventive interventions will take between 4 and 8 weeks to complete. Outcome assessments take place in all participants at baseline (T0) and post-intervention (T1), as well as at 3-month (T2) and 9-month (T3) follow-up. Some outcomes are assessed at all time points, while others are only assessed at baseline (T0) and 9-month follow-up (T3).

The primary outcome measure are depression symptoms, assessed with the Patient Health Questionnaire (PHQ-9) at post-intervention and at 3-month follow-up. Secondary outcomes include depressive symptoms at 9-month follow-up as well as bipolar mood disorder symptoms, psychosocial functioning, and usage of adaptive coping strategies across all time points. These secondary outcomes are also assessed using self-report questionnaires. The potential onset of a mood disorder is assessed as a secondary outcome using a clinical interview at 9-month follow-up. This interview is only conducted with participants who show significant mood disorder symptoms at any of the 4 time points, indicated by a PHQ-9 score of 5 and above.

With this RCT design, the researchers can assess if access to a platform with three online preventive interventions can help in preventing mood disorder symptoms in COPMI. This can deepen the understanding of vulnerabilities and needs for this high-risk population, which will hopefully contribute to improved long-term mental health outcomes.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

154

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

10 jaar tot 25 jaar (Kind, Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Child has a parent with psychiatric problems, based on the child's report during the recruitment process
  • Child is in the age range of 10 - 25 years
  • Written informed consent of child (For children aged 12 to 25) and their parent(s) or legal guardian(s) (for children aged 10 to 16).
  • Access to a laptop, tablet or mobile phone during the study period
  • Ability to speak and write in the Dutch language

Exclusion Criteria:

- Current depressive or bipolar disorder diagnosis and/or suicidality based on the K-SADS psychiatric interview that is conducted at baseline. In case of a mild current depressive episode during the interview, the researchers will ask participants about agreeing to another K-SADS psychiatric interview (on mood symptoms and suicidality) after a period of 6 months. If participants agree, and there is no current mood episode after the 6 months waiting period according to the K-SADS psychiatric interview, participants are eligible to participate in the study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: MARIO platform including three online interventions

In this study, the researchers will be investigating the MARIO preventive intervention platform. This platform offers up to three types of preventive intervention components.

The first preventive intervention component is KOPPsupport, an existing psycho-educational program for COPMI in the age of 16-25 years. The duration of the intervention is ~8 weeks.

The second preventive intervention component is Moodpep, an intervention with cognitive behavioural therapy elements for individuals aged 18 years and older. It consists of 7 weekly modules which will take between 6-10 weeks to complete.

The third preventive intervention component is the Grow It! app. It is an interactive tool, developed for youth in the age of 10 to 25 years. The app consists of three major components:

  1. Increasing affective awareness through ESM surveys
  2. Improving emotional reflection through individualized mood profiles
  3. Strengthening adaptive coping strategies through CBT-based challenges

KOPPsupport is an existing psycho-educational program for COPMI, developed by the Trimbos institute for participants aged 16 to 25 years (Woolderink et al., 2010). It is designed to strengthen protective factors to prevent mental health issues. Registration occurs via the MARIO platform, after which participants are redirected to the KOPPsupport website (https://www.koppsupport.nl/) where they can sign up for a specific starting date. Depending on group start dates, participants may wait for up to 4 weeks before starting the intervention. The intervention itself consists of eight weekly online chat group meetings, guided by mental health professionals. The sessions cover topics including thoughts and feelings, questions about addictions and mental problems, roles in the family, and different styles of behavior. Before each session, participants are also required to carry out homework assignments about the topic that will subsequently be discussed in that session.

Moodpep is an online preventive intervention with CBT-based elements (VUmc; Garnefski & Kraaij, 2023). While Moodpep is developed for individuals aged 18 years and older, participants younger than 18 can still select it on the MARIO intervention platform. It consists of 7 different modules in a fixed order that participants are instructed to complete within 8 weeks. The CBT-based modules aim to encourage new activities, improve relaxation, reduce negative thoughts, and assist in working towards personal goals. Tasks within the modules include the completion of a daily diary, different psychoeducational exercises, and suggestions for COPMI to develop ideas about reaching personal goals. Users are also in regular online contact with a trained coach who is a member of the MARIO research team. The coach gives asynchronous feedback within 3 working days about the participants' completed modules, is available to talk about potential problems, and encourages continued participation.

Grow It! is a gamified smartphone app for youth between the ages of 10 and 25 years. The app consists of three major components: 1) Increasing affective awareness via ESM surveys; 2) improving emotional reflection via a personalized visual mood profile; and 3) improving adaptive coping through daily CBT-based challenges.

To improve app interactivity, fun, and user friendliness, the app includes the choice for an avatar and other ways to personalize the app. Participants use the Grow It! app for four weeks. There must be at least 4 people available to build a team for the intervention to start. If less than 4 people sign up over the course of these four weeks, the remaining spots are filled by members of the research team who are instructed to also use Grow It! regularly during the intervention period.

Geen tussenkomst: Control Condition

Participants who are assigned to the control condition do not receive access to the MARIO preventive intervention platform. During the 12 months of the study, participants get regular care if needed via the health care system in place. After 12 months, the researchers inform participants about the three online interventions, so that participants can use them independently from the MARIO study, in case these participants want to do so and are eligible for participation in the preventive intervention.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Development of depressive symptoms post-intervention and at 3-month follow-up
Tijdsspanne: Measurement at baseline (Month 0), post-intervention (T1; Month 3), and 3-month follow-up (T2; Month 6).

Depressive symptoms post-intervention and at 3-month follow-up are measured with the Patient Health Questionnaire 9 (PHQ-9; Kroenke et al, 2001). Participants indicate how often they experienced symptoms (e.g., "How often in the past two weeks did you have little interest or pleasure in things that you do?") on a 4-point scale (0 = not at all, 1 = on some days, 2 = more than half of the days, 3 = (almost) every day). The original nine items were extended to ten items, by rephrasing some of the items and splitting item 8 ("How often in the past two weeks were you moving or speaking so slowly that other people could have noticed, or the opposite - were you so fidgety or restless that you have been moving around a lot more than usual?") into two questions (Items 8a and 8b). A higher total score across all items indicated higher depressive symptoms. However, scores on items 8a and 8b were converted into a singular score by selecting the item that was scored higher by each participant.

Measurement at baseline (Month 0), post-intervention (T1; Month 3), and 3-month follow-up (T2; Month 6).

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Depressive symptoms at 9-month follow-up
Tijdsspanne: At 9-month follow-up (T3; Month 12)

Depressive symptoms at 9-month follow-up are measured with the PHQ-9 as well. Participants indicate how often they experienced depressive symptoms (e.g., "How often in the past two weeks did you have little interest or pleasure in things that you do?") on a 4-point scale (0 = not at all, 1 = on some days, 2 = more than half of the days, 3 = (almost) every day). The original nine items were extended to ten items, by rephrasing some of the items and splitting item 8 ("How often in the past two weeks were you moving or speaking so slowly that other people could have noticed, or the opposite - were you so fidgety or restless that you have been moving around a lot more than usual?") into two separate questions (Items 8a and 8b). A higher total score across all items indicated higher depressive symptoms. However, scores on items 8a and 8b were converted into a singular score by selecting the item that was scored higher by each participant.

At 9-month follow-up (T3; Month 12)
Bipolar mood disorder symptoms
Tijdsspanne: At baseline (Month 0), post-intervention (T1; Month 3), 3-month follow-up (T2; Month 6), and 9-month follow-up (T3; Month 12).

Bipolar mood disorder symptoms are measured with the MARIO-check at all time-points, consisting of depression items from the PHQ-9 and mania items from the K-SADS COMP (Townsend et al., 2020) and GBI (Depue et al, 1981). The mania items capture decreased need for sleep, racing thoughts, and increases in energy and goal-directed activity. One item assesses psychotic-like symptoms. Participants indicate how often they experienced these symptoms on a 4-point scale (0 = not at all, 1 = on some days, 2 = more than half of the days, 3 = (almost) every day). A higher score across all 4 items indicates higher bipolar mood disorder symptoms.

At baseline (Month 0), post-intervention (T1; Month 3), 3-month follow-up (T2; Month 6), and 9-month follow-up (T3; Month 12).
Adaptive coping
Tijdsspanne: At baseline (Month 0), post-intervention (T1; Month 3), 3-month follow-up (T2; Month 6), and 9-month follow-up (T3; Month 12).

The usage of adaptive coping strategies is measured at all time points by items from the Utrecht Coping List Adolescent version (Bijstra et al., 1994). The scale consists of 47 items. 21 items measure adaptive coping strategies (e.g., "When I have a problem, I try to think of concrete ways to solve it."), while 26 items measure maladaptive coping strategies (e.g., "I feel overwhelmed and don't know what to do."). Items are scored on a scale from 1 (never) to 4 (very often), with total scores of the subscales indicating higher adaptive coping (scores from 21 to 84) and maladaptive coping (scores from 26 to 104), respectively.

At baseline (Month 0), post-intervention (T1; Month 3), 3-month follow-up (T2; Month 6), and 9-month follow-up (T3; Month 12).
Psychosocial functioning
Tijdsspanne: At baseline (Month 0), post-intervention (T1; Month 3), 3-month follow-up (T2; Month 6), and 9-month follow-up (T3; Month 12).

Psychosocial functioning is assessed at all time points with 10 items from the PROMIS pediatric Fatigue item bank (Lai et al., 2013). Participants rate items (e.g., "I had enough energy to do my usual things at home") on a scale from 0 (never) to 4 (almost always), with higher total scores of all items (0 to 40) indicating higher psychosocial functioning.

At baseline (Month 0), post-intervention (T1; Month 3), 3-month follow-up (T2; Month 6), and 9-month follow-up (T3; Month 12).
The likelihood of onset of a mood disorder at 9-month follow-up
Tijdsspanne: PHQ-9 at baseline (Month 0), post-intervention (T1; Month 3), 3-month follow-up (T2; M), and 9-month follow-up (T3; Month 12). If participants report a PHQ-9 score of 5 or above at any time point a K-SADS diagnostic interview is conducted at Month 12.

Onset of depression or bipolar disorder is measured using the depression and mania sections of the computerized version of the K-SADS diagnostic interview (Kaufman et al., 1997). These sections include questions about a variety of current (in the past two weeks; at T3 over the past 12 months) and lifetime depression and mania symptoms. The sections also assess potential current and past suicidality and self-harm in participants. The interview is conducted for all participants as part of the screening procedure at T0, and at T3 for all participants who received a PHQ-9 score ≥ 5 (indicating mild depressive symptoms) in the MARIO-check at any of the time points. Interviews are conducted on the phone by a member of the research team and take approximately 20 to 30 minutes to complete.

PHQ-9 at baseline (Month 0), post-intervention (T1; Month 3), 3-month follow-up (T2; M), and 9-month follow-up (T3; Month 12). If participants report a PHQ-9 score of 5 or above at any time point a K-SADS diagnostic interview is conducted at Month 12.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

29 november 2022

Primaire voltooiing (Geschat)

1 april 2027

Studie voltooiing (Geschat)

1 april 2027

Studieregistratiedata

Eerst ingediend

4 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

9 november 2026

Eerst geplaatst (Werkelijk)

16 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

9 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

Individual participant data can be shared upon request to the principal investigators at mario@amsterdamumc.nl. Researchers who are interested in the data need to submit a detailed statistical analysis plan, outlining which variables are of interest to answer specific research questions and to test specific hypotheses. Both internal and external researchers can only receive data if the Principal Investigators have approved this analysis plan. Privacy-sensitive data will not be shared outside the MARIO data management team. Primary and secondary outcome data will not be shared with researchers (internal or external) before conclusion of data collection on April 1st, 2027.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren